Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response
Crossref DOI link: https://doi.org/10.1007/s10014-017-0284-x
Published Online: 2017-04-06
Published Print: 2017-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Tamura, Ryota
Tanaka, Toshihide
Miyake, Keisuke
Yoshida, Kazunari
Sasaki, Hikaru
License valid from 2017-04-01